Page last updated: 2024-12-08
iridomyrmecin
Description
iridomyrmecin: produced by the Drosophila parasitoid Leptopilina heterotoma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Flora | Rank | Flora Definition | Family | Family Definition |
Heterotoma | genus | [no description available] | Campanulaceae | A plant family of the order Campanulales, subclass Asteridae, class Magnoliopsida[MeSH] |
Cross-References
ID Source | ID |
PubMed CID | 442427 |
CHEBI ID | 5967 |
SCHEMBL ID | 1649438 |
MeSH ID | M0577344 |
Synonyms (21)
Synonym |
iridomyrmexin |
iridomyrmecin |
C09786 , |
485-43-8 |
AC1L9CSW , |
(4s,4as,7s,7ar)-4,7-dimethyl-4,4a,5,6,7,7a-hexahydro-1h-cyclopenta[c]pyran-3-one |
nsc 10974 |
9736r92epu , |
cyclopenta(c)pyran-3(1h)-one, hexahydro-4,7-dimethyl-, (4s-(4alpha,4abeta,7beta,7abeta))- |
(+)-iridomyrmecin |
unii-9736r92epu |
SCHEMBL1649438 |
CHEBI:5967 |
cyclopenta(c)pyran-3(1h)-one, hexahydro-4,7-dimethyl-, (4s,4as,7s,7ar)- |
cyclopenta(c)pyran-3(1h)-one, hexahydro-4,7-dimethyl-, (4s-(4.alpha.,4a.beta.,7.beta.,7a.beta.))- |
.alpha.-(2-hydroxymethyl-3-methylcyclopentane)propionic acid .delta.-lactone |
iridomyrmecin [mi] |
iridomyrmecin, (+)- |
surecn1649438 |
DTXSID40876125 |
Q2016116 |
Drug Classes (1)
Class | Description |
terpene lactone | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 25.26
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 25.26 (24.57) | Research Supply Index | 2.40 (2.92) | Research Growth Index | 4.32 (4.65) | Search Engine Demand Index | 26.67 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |